Does inflammation determine metabolic health status in obese and nonobese adults?

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages

  Phillips, Catherine M ^a   Perry, Ivan J ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; CYTOKINE; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METABOLISM; OBESITY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PUBLIC HEALTH; SMOKING;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885206610     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2038     Document Type: Article

References (46)

1. Mokdad AH, Ford ES, Bowman B.A., et al Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289: 76-79.
2. Van GaalLF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880.
3. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese, " normal-weight individual. Am J Clin Nutr. 1981; 34: 1617-1621.
4. Wildman RP, Muntner P, Reynolds K., et al The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168: 1617-1624.
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-867.
6. Aguilar-Salinas C.A., Garcia EG, Robles L, et al High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008; 93: 4075-4079.
7. Doumatey AP, Bentley AR, Zhou J, Huang H., Adeyemo A, Rotimi CN Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. J Endocrinol Metab. 2012; 2: 51-65.
8. Karelis AD, Faraj M, Bastard J.P., et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005; 90: 4145-4150.
9. Koster A, Stenholm S, Alley D.E., et al Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring). 2010; 18: 2354-2361.
10. Shin MJ, Hyun YJ, Kim O.Y., Kim JY, Jang Y, Lee JH Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond). 2006; 30: 1529-1534.
11. Wildman RP, Kaplan R, Manson J.E., et al. Body size phenotypes and inflammation in the Women's Health Initiative Observational Study. Obesity (Silver Spring). 2011; 19: 1482-1491.
12. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obes (Lond). 2010; 34(SUPPL. 2): S18-S23.
13. Velho S, Paccaud F, Waeber G., Vollenweider P, Marques-Vidal P. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 2010; 64: 1043-1051.
14. Hinnouho GM, Czernichow S, Dugravot A., Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care. 2013; 36: 2294-2300.
15. Lopez-Miranda J., Perez-Martinez P. It is time to define metabolically obese but normal-weight (MONW) individuals. Clin Endocrinol (Oxf). 2013; 79: 314-315.
16. Meigs JB, Wilson PW, Fox C.S., et al Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006; 91: 2906-2912.
17. Marques-Vidal P, Velho S, Waterworth D, Waeber G, von Kanel R, Vollenweider P. The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr. 2012; 66: 426-435.
18. Kearney PM, Harrington JM, McCarthy V.J., Fitzgerald AP, Perry IJ Cohort profile: the Cork and Kerry Diabetes and Heart Disease Study [published online ahead of print September 24, 2012]. Int J Epidemiol. doi:10.1093/ije/dys131.
19. Craig CL, Marshall AL, Sjostrom M, et al International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35: 1381-1395.
20. Villegas R, Salim A, Collins M.M., Flynn A., Perry IJ. Dietary patterns in middle-aged Irish men and women defined by cluster analysis. Public Health Nutr. 2004; 7: 1017-1024.
21. Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify meta-bolically healthy but obese individuals (MHO)? Diabetes Metab. 2004; 30: 569-572.
22. Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia. 2012; 55: 881-884.
23. Yang Y, Lu HL, Zhang J, et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond). 2006; 30: 439-446.
24. Masharani UB, Maddux BA, Li X, et al Insulin resistance in non-obese subjects is associated with activation of the JNK pathway and impaired insulin signaling in skeletal muscle. PloS One. 2011; 6: e19878.
25. Phillips CM, Goumidi L, Bertrais S., et al Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. Am J Clin Nutr. 2009; 90: 1665-1673.
26. Phillips CM, Kesse-Guyot E, Ahluwalia N., et al Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk. Atherosclerosis. 2012; 220: 513-519.
27. Muscari A, Bozzoli C, Puddu G.M., et al Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995; 98: 357-364.
28. van Greevenbroek M.M., Jacobs M, van der Kallen CJ, et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol. 2012; 154: 158-162.
29. Deleskog A, Piksasova O, Silveira A., et al Serum 25-hydroxyvitamin D concentration, established and emerging cardiovascular risk factors and risk of myocardial infarction before the age of 60 years. Atherosclerosis. 2012; 223: 223-229.
30. Patterson CC, Smith AE, Yarnell J.W., Rumley A., Ben-Shlomo Y, Lowe GD. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caer-philly Study. Atherosclerosis. 2010; 209: 551-557.
31. O'Connell J., Lynch L, Hogan A., Cawood TJ, O'Shea D. Preadi-pocyte factor-1isassociated with metabolic profileinsevere obesity. J Clin Endocrinol Metab. 2011; 96: E680-E684.
32. Kizer JR, Benkeser D, Arnold A.M., et al Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation. 2012; 126: 2951-2961.
33. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007; 167: 1510-1517.
34. Asterholm IW, Scherer PE Enhanced metabolic flexibility associated with elevated adiponectin levels. AmJPathol. 2010; 176: 1364-1376.
35. Lynch LA, O'Connell JM, Kwasnik AK, Cawood T.J., O'Farrelly C, O'Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring). 2009; 17: 601-605.
36. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010; 116: 529-536.
37. Cushman M, Lemaitre RN, Kuller L.H., et al Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999; 19: 493-498.
38. Shea JL, Randell EW, Sun G. The prevalence of metabolically healthy obese subjects defined by BMI and dual-energy x-ray absorptiometry. Obesity (Silver Spring). 2011; 19: 624-630.
39. Arnlov J, Sundstrom J, Ingelsson E., Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middleaged men. Diabetes Care. 2011; 34: 61-65.
40. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012; 97: 2482-2488.
41. Appleton SL, Seaborn CJ, Visvanathan R, et al Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013; 36: 2388-2394.
42. Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, et al Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013; 98: 2318-2325.
43. Kantartzis K, Machann J, Schick F., et al Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia. 2011; 54: 864-868.
44. Phillips CM, Tierney AC, Perez-Martinez P, et al Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring). 2013; 21: E154-E161.
45. Robinson LE, Mazurak VC N-3 polyunsaturated fatty acids: relationship to inflammation in healthy adults and adults exhibiting features of metabolic syndrome. Lipids. 2013; 48: 319-332.
46. Oliver E, McGillicuddy FC, Harford K.A., et al Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC n-3 PUFA. J Nutr Biochem. 2012; 23: 1192-1200.